Double-blind, placebo-controlled study to investigate safety, tolerability, immunogenicity and clinical efficacy of a specific immunotherapy combining allergen with CYT003-QbG10 (CYT005-AllQbG10) in adult patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy

Trial Profile

Double-blind, placebo-controlled study to investigate safety, tolerability, immunogenicity and clinical efficacy of a specific immunotherapy combining allergen with CYT003-QbG10 (CYT005-AllQbG10) in adult patients with perennial allergic rhinoconjunctivitis due to house dust mite allergy

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs CYT 005 AllQbG10 (Primary) ; House dust mite allergy immunotherapy; Vaccines
  • Indications Hypersensitivity; Perennial allergic rhinitis; Rhinoconjunctivitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 May 2009 Additional lead investigator (Mueller P) identified as reported by ClinicalTrials.gov
    • 10 Jul 2008 Status changed from in progress to completed, based on results data reported in Cytos media release.
    • 21 Jun 2008 Status changed from recruiting to in progress, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top